19-11113743-G-C
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PP3PP4PM5
This summary comes from the ClinGen Evidence Repository: The NM_000527.5(LDLR): c.1567G>C (p.Val523Leu) variant is classified as Likely Pathogenic for Familial Hypercholesterolemia by applying ACMG/AMP evidence codes PM2, PM5, PP3 and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (specification version 1.2) on 27 January 2023. The supporting evidence is as follows: PM2: PopMax MAF = 0.00003 in South Asian exomes (gnomAD v2.1.1).PP3: REVEL = 0.904. PM5: There is 1 missense variant in the same codon, NM_000527.5(LDLR):c.1567G>A (p.Val523Met), classified as Pathogenic by these guidelines.PP4: Variant meets PM2 and is identified in 1 patient with possible FH by Simon Broome criteria from PMID 26748104 (Reiman et al., 2016). LINK:https://erepo.genome.network/evrepo/ui/classification/CA034835/MONDO:0007750/013
Frequency
Consequence
NM_000527.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.1567G>C | p.Val523Leu | missense_variant | 10/18 | ENST00000558518.6 | NP_000518.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LDLR | ENST00000558518.6 | c.1567G>C | p.Val523Leu | missense_variant | 10/18 | 1 | NM_000527.5 | ENSP00000454071.1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152194Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251336Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135872
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461630Hom.: 0 Cov.: 34 AF XY: 0.00 AC XY: 0AN XY: 727128
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152194Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74346
ClinVar
Submissions by phenotype
Familial hypercholesterolemia Pathogenic:1Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham | Aug 03, 2023 | This variant located in exon 10 of the LDLR gene, results from a G to C substitution at nucleotide position 1567.This variant and another variant resulting in the same amino acid change (c.1567G>T) have been reported in familial hypercholesterolemia cohorts. Another alteration at the same codon, p.V523M (c.1567G>A), has been been reported in the homozygous and heterozygous states in multiple individuals with familial hypercholesterolemia - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 07, 2023 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Val523 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 2088165, 14974088, 15256764, 21310417, 21865347, 22294733, 23375686, 25463123, 27765764). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function. ClinVar contains an entry for this variant (Variation ID: 993226). This missense change has been observed in individual(s) with clinical features of familial hypercholesterolaemia (PMID: 26748104). This variant is present in population databases (rs28942080, gnomAD 0.003%). This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 523 of the LDLR protein (p.Val523Leu). - |
Hypercholesterolemia, familial, 1 Pathogenic:1
Likely pathogenic, reviewed by expert panel | curation | ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel | Jan 27, 2024 | The NM_000527.5(LDLR): c.1567G>C (p.Val523Leu) variant is classified as Likely Pathogenic for Familial Hypercholesterolemia by applying ACMG/AMP evidence codes PM2, PM5, PP3 and PP4 as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (specification version 1.2) on 27 January 2023. The supporting evidence is as follows: PM2: PopMax MAF = 0.00003 in South Asian exomes (gnomAD v2.1.1). PP3: REVEL = 0.904. PM5: There is 1 missense variant in the same codon, NM_000527.5(LDLR):c.1567G>A (p.Val523Met), classified as Pathogenic by these guidelines. PP4: Variant meets PM2 and is identified in 1 patient with possible FH by Simon Broome criteria from PMID 26748104 (Reiman et al., 2016). - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Dec 13, 2019 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 09, 2023 | The p.V523L variant (also known as c.1567G>C), located in coding exon 10 of the LDLR gene, results from a G to C substitution at nucleotide position 1567. The valine at codon 523 is replaced by leucine, an amino acid with highly similar properties. This variant and another variant resulting in the same amino acid change (c.1567G>T) have been reported in familial hypercholesterolemia cohorts, but clinical details were limited (Marduel M et al. Hum Mutat, 2010 Nov;31:E1811-24; Pandey S et al. J Appl Lab Med, 2016 Sep;1:109-118; Reiman A et al. Ann Clin Biochem, 2016 Nov;53:654-662; Leren TP et al. Atherosclerosis, 2021 Apr;322:61-66). Another alteration at the same codon, p.V523M (c.1567G>A), has been been reported in the homozygous and heterozygous states in multiple individuals with familial hypercholesterolemia (e.g., Hobbs HH et al. Hum. Mutat., 1992;1:445-66; Lombardi P et al. J. Lipid Res., 1995 Apr;36:860-7; Luirink IK et al. J Clin Lipidol Dec;13:272-278). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at